Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer (ACTREC) and Tata Memorial Hospital, Tata Memorial Centre, Mumbai, India.
Neurol India. 2012 Jan-Feb;60(1):61-5. doi: 10.4103/0028-3886.93594.
There is significant inter-observer variation amongst the neuro-pathologists in the typing, subtyping, and grading of glial neoplasms for diagnosis. Centralized pathology review has been proposed to minimize this inter-observer variation and is now almost mandatory for accrual into multicentric trials. We sought to assess the concordance between neuro-pathologists on histopathological diagnosis of glioblastoma.
Comparison of local, institutional, and central neuro-oncopathology reporting in a cohort of 34 patients with newly diagnosed supratentorial glioblastoma accrued consecutively at a tertiary-care institution on a prospective trial testing the addition of a new agent to standard chemo-radiation regimen.
Concordance was sub-optimal between local histological diagnosis and central review, fair between local diagnosis and institutional review, and good between institutional and central review, with respect to histological typing/subtyping. Twelve (39%) of 31 patients with local histological diagnosis had identical tumor type, subtype and grade on central review. Overall agreement was modestly better (52%) between local diagnosis and institutional review. In contrast, 28 (83%) of 34 patients had completely concordant histopathologic diagnosis between institutional and central review. The inter-observer reliability test showed poor agreement between local and central review (kappa statistic=0.12, 95% confidence interval (CI): -0.03-0.32, P=0.043), but moderate agreement between institutional and central review (kappa statistic=0.51, 95%CI: 0.17-0.84, P=0.00003). Agreement between local diagnosis and institutional review was fair.
There exists significant inter-observer variation regarding histopathological diagnosis of glioblastoma with significant implications for clinical research and practice. There is a need for more objective, quantitative, robust, and reproducible criteria for better subtyping for accurate diagnosis.
神经病理学家在胶质肿瘤的分型、亚型和分级诊断方面存在显著的观察者间差异。为了最小化这种观察者间的差异,已经提出了集中病理审查,并且现在几乎是加入多中心试验的必要条件。我们旨在评估神经病理学家在胶质母细胞瘤的组织病理学诊断方面的一致性。
在一项前瞻性试验中,对连续入组的 34 例新诊断的幕上胶质母细胞瘤患者的局部、机构和中枢神经肿瘤学报告进行比较,该试验旨在测试将新药物加入标准放化疗方案中。
局部组织学诊断与中心审查之间的一致性不理想,局部诊断与机构审查之间的一致性一般,机构和中心审查之间的一致性良好,涉及组织学分型/亚型。31 例具有局部组织学诊断的患者中,有 12 例(39%)在中心审查中具有相同的肿瘤类型、亚型和分级。局部诊断与机构审查之间的总体一致性略好(52%)。相比之下,28 例(83%)患者在机构和中心审查之间具有完全一致的组织病理学诊断。观察者间可靠性检验显示局部和中心审查之间的一致性较差(kappa 统计量=0.12,95%置信区间(CI):-0.03-0.32,P=0.043),而机构和中心审查之间的一致性适中(kappa 统计量=0.51,95%CI:0.17-0.84,P=0.00003)。局部诊断和机构审查之间的一致性一般。
胶质母细胞瘤的组织病理学诊断存在显著的观察者间差异,这对临床研究和实践具有重要意义。需要更客观、定量、稳健和可重复的标准来进行更好的分型,以进行准确的诊断。